Monjuvi: CD19-targeted lymphoma therapy for relapsed DLBCL patients in the U.S.

Responsible: ad hoc news Classics & Long-sellers Desk. Reviewed prior to publication on June 14, 2026 at 11:51:23 AM ET. Details in the imprint.

Monjuvi (tafasitamab-cxix) has become a key targeted option for certain adults in the United States living with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), one of the most aggressive forms of non-Hodgkin lymphoma. Used in combination with lenalidomide, the antibody therapy is FDA-approved for patients who are not eligible for an autologous stem cell transplant, giving oncologists an off-the-shelf alternative in later treatment lines. Developed by MorphoSys AG together with its partner Incyte, Monjuvi is supplied as an intravenous infusion and is available through U.S. hospital and community oncology infusion centers via specialty distribution. For U.S. patients and caregivers, the product sits in a niche between traditional chemoimmunotherapy and more complex cell-based treatments.

What Monjuvi is designed to do in relapsed or refractory DLBCL

Monjuvi is a humanized, Fc-modified monoclonal antibody that specifically targets the CD19 antigen on the surface of malignant B cells, including those seen in DLBCL. By binding to CD19, the drug is intended to help the immune system recognize and destroy cancerous B cells, complementing the immunomodulatory action of lenalidomide used in combination. According to the U.S. prescribing information summarized by MorphoSys and Incyte, Monjuvi is indicated for adults with relapsed or refractory DLBCL not otherwise specified, including DLBCL that arises from low-grade lymphoma, after at least one line of systemic therapy, when they are not candidates for autologous stem cell transplant. That label places the medicine squarely in the second-line or later space for patients whose disease has returned or not responded to previous regimens.

The U.S. Food and Drug Administration granted Monjuvi its initial approval in July 2020, marking the therapy's entry into a growing field of CD19-targeted and other novel agents for DLBCL. The drug is classified as a prescription oncology biologic and is typically reimbursed under the medical benefit in the U.S. health system, with net treatment costs varying by payer, contract, and site of care rather than a single standard list price. As a specialty infused medicine, administration happens under the supervision of oncology teams in hospital outpatient departments or community infusion centers, rather than at home. For many community-based oncologists, this setup aligns with existing infusion workflows for other antibody and chemo regimens.

Clinical evidence supporting Monjuvi's approval includes data from patients with relapsed or refractory DLBCL who had received at least one prior systemic therapy and were not eligible for autologous stem cell transplant, showing responses when the drug was combined with lenalidomide in this setting. While detailed response rates, duration of response, and survival metrics are set out in the full prescribing information and clinical publications, the core rationale of the regimen is to pair a CD19-directed antibody with an immunomodulatory backbone for patients who might otherwise have limited options beyond traditional chemotherapy. In an environment where CAR-T cell therapies, other antibodies, and small molecules all compete for use, Monjuvi's positioning highlights its off-the-shelf nature and intravenous route without the need for personalized cell manufacturing.

From a market perspective, diffuse large B-cell lymphoma therapeutics represent a multibillion-dollar global segment as of the mid-2020s, reflecting the disease's status as the most common subtype of non-Hodgkin lymphoma. Industry analysts project that the DLBCL therapeutics market could grow from several billion dollars in the mid-2020s to substantially higher levels by the end of the decade as more targeted agents and combination regimens enter clinical practice. Within this landscape, MorphoSys and its U.S. affiliate have positioned Monjuvi as part of a broader push into oncology, focusing on specific patient populations and integrating the therapy into relevant treatment algorithms through collaborations with hematology-oncology centers. For clinicians, the decision to use Monjuvi often depends on prior treatment history, transplant eligibility, comorbidities, and access to competing modalities in their institution.

Monjuvi is prescribed in combination with lenalidomide for a defined number of cycles, followed by Monjuvi monotherapy until disease progression or unacceptable toxicity, in line with its U.S. label. This structure means that dosing schedules and monitoring requirements are critical parts of practice, particularly in the first months of therapy when infusion frequency is higher. Infusion-related reactions, cytopenias, infections, and other adverse events typical of antibody-based and immunomodulatory regimens must be managed according to clinical guidelines, and healthcare professionals rely on the detailed safety and dosing instructions provided in the product's official information. Patients receive the medicine only on prescription, and supportive care, laboratory monitoring, and follow-up imaging are integral elements of the care pathway.

For MorphoSys AG, Monjuvi is one of its signature oncology products, reflecting years of antibody discovery and development that the company has pursued in hematologic malignancies. As a commercial-stage biologic with an established U.S. indication, the product plays a strategic role in showcasing the firm's capabilities in targeted therapies for B-cell cancers, in partnership with Incyte for commercialization in key markets. Shares of MorphoSys AG (DE0006632003, ticker MOR) traded at levels quoted on Nasdaq in recent sessions according to public market data, providing equity investors with exposure to the company's oncology portfolio alongside Monjuvi and other pipeline assets.

This article was created with a.i. assistance and editorially reviewed. Product information is provided without warranty; prices and availability may change at any time. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.